Graphene Photothermal Adjuvant Therapy for Mild Corona Virus Disease 2019: A Prospective Randomized Controlled Trial

Launched by SOUTHEAST UNIVERSITY, CHINA · Dec 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called graphene photothermal adjuvant therapy for people with mild COVID-19 symptoms. The goal is to see if this therapy can help patients recover faster and test negative for the virus sooner than those receiving standard treatment alone. Participants in the study will be divided into two groups: one group will receive the new graphene therapy along with regular care, while the other group will only receive the usual treatment. Each participant in the treatment group will undergo 30 minutes of the graphene therapy each day for a week.

To be eligible for this trial, participants must be between 18 and 60 years old, have mild COVID-19 symptoms, and have tested positive for the virus within the last 48 hours. However, those with severe COVID-19, certain heart or lung conditions, uncontrolled high blood pressure or diabetes, or other serious health issues cannot join. Pregnant women and those with specific infections will also be excluded. If you are interested in participating, you can expect to receive either the new therapy or standard care while helping researchers learn more about this potential treatment for COVID-19.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meet the diagnostic criteria for mild COVID-19.
• • Patients aged 18-60 years (inclusive).
• • No later than 48 h after testing positive and the onset of clinical symptoms
• • Sign informed consent form.
• Exclusion Criteria:
• • Severe or critically patients with COVID-19.
• • Resting heart rate over 120 beats per minute.
• • Coronary heart disease patients with acute cardiac insufficiency.
• • Acute exacerbation of chronic obstructive pulmonary disease（COPD）.
• • Uncontrolled hypertension \[resting systolic blood pressure(SBP) more than 180 mmHg and diastolic blood pressure(DBP) more than 90 mmHg\]; uncontrolled diabetes(Random Plasma Glucose, RPG\>16.7mmol/L, HbA1C\>7.0%)
• • Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases.
• • Pregnant or menstruating woman.
• • Known or suspected history of active tuberculosis or extrapulmonary tuberculosis, patients with brucellosis, pneumonia-related illness from other causes
• • COVID-19 patients for the second or more times
• • Those who cannot cooperate due to various reasons
• • Body temperature: more than 38℃.

Trial Officials